CC BY 4.0 · Pharmaceutical Fronts 2020; 02(01): e64-e76 DOI: 10.1055/s-0040-1708527
Original Article
Georg Thieme Verlag KG Stuttgart · New York
Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities
Xianglei Liu
1
Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
,
Tianyuan Sun
1
Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
,
Qiuhan Ge
1
Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
,
Jianwei Zhu
1
Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
2
Jecho Laboratories, Inc. Maryland, United States
3
Jecho Biopharmaceuticals Co., Ltd., Tianjin, China
› Author AffiliationsFunding This work was supported by the China Postdoctoral Science Foundation (2016M600319) and Natural Science Foundation of China (81473127&81773621).
The development of bispecific antibodies (BsAbs) has had a profound impact on cancer immunotherapy. Single-domain antibodies (SdAbs) could offer advantages over other antibody formats for the generation of a BsAbs, such as small size (∼12–15 kDa), with high affinity and specificity, superior accessibility, and high yield expression in bacteria. In this study, VEGFR2 and CD16 were chosen as the targets to construct BsAbs. As the rationale, VEGFR2 is critical for tumor-associated angiogenesis, and CD16 expressed on natural killer cells is an important target on immune cells. Humanized anti-VEGFR2 SdAb 3VGR19 and anti-CD16 SdAb C21 were combined to construct several bispecific SdAbs (BiSdAbs). The biochemical properties of the BiSdAbs were characterized. They retained the high affinity for both targets, binding selectivity, and antiangiogenic activity such as inhibition of cell proliferation, migration, endothelial tube formation, angiogenesis, and cytotoxicity to cancer cells in vitro, indicating that BiSdAbs could be a potential alternative for cancer therapy.
X.L. designed and conducted the experiments, analyzed the data, and drafted the manuscript; T.S. and Q. G. performed some of the experiments. J.Z. supervised project, analyzed data, critically discussed, and revised the manuscript. All authors read and approved the final manuscript.
3
Klinger M,
Benjamin J,
Kischel R,
Stienen S,
Zugmaier G.
Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions. Immunol Rev 2016; 270 (01) 193-208
4
Han L,
Chen J,
Ding K.
, et al. Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system. Sci Rep 2017; 7 (01) 8360
13
Klingemann H,
Boissel L,
Toneguzzo F.
Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol 2016; 7: 91
15
Ferrari de Andrade L,
Tay RE,
Pan D.
, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science 2018; 359 (6383): 1537-1542
16
Smits NC,
Coupet TA,
Godbersen C,
Sentman CL.
Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. Expert Opin Biol Ther 2016; 16 (09) 1105-1112
18
Wu J,
Fu J,
Zhang M,
Liu D.
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol 2015; 8: 96
19
Pahl J,
Reusch U,
Gantke T.
, et al. AFM13 is the most advanced bispecific NK-cell engaging antibody in clinical development substantially enhancing NK-cell effector function and proliferation. Blood 2016; 128: 1764
23
Ferrara N,
Hillan KJ,
Gerber HP,
Novotny W.
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3 (05) 391-400
24
Verdaguer H,
Tabernero J,
Macarulla T.
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol 2016; 8 (03) 230-242
26
Allegra A,
Innao V,
Gerace D,
Vaddinelli D,
Allegra AG,
Musolino C.
Nanobodies and cancer: current status and new perspectives. Cancer Invest 2018; 36 (04) 221-237
27
Steeland S,
Vandenbroucke RE,
Libert C.
Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today 2016; 21 (07) 1076-1113
28
Kijanka M,
Dorresteijn B,
Oliveira S,
van Bergen en Henegouwen PM.
Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond) 2015; 10 (01) 161-174
30
Hassanzadeh-Ghassabeh G,
Devoogdt N,
De Pauw P,
Vincke C,
Muyldermans S.
Nanobodies and their potential applications. Nanomedicine (Lond) 2013; 8 (06) 1013-1026
33
Ren X,
Xie W,
Wang Y.
, et al. VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells. Immunol Res 2016; 64 (04) 1060-1070
34
Xie W,
Liu F,
Wang Y.
, et al. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget 2016; 7 (13) 16445-16461
35
Behdani M,
Zeinali S,
Khanahmad H.
, et al. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol 2012; 50 (1–2): 35-41
37
Behar G,
Sibéril S,
Groulet A.
, et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008; 21 (01) 1-10
38
Geng S,
Wang Y,
Wang L.
, et al. A light-responsive self-assembly formed by a cationic azobenzene derivative and SDS as a drug delivery system. Sci Rep 2017; 7: 39202
39
Lefranc MP,
Ehrenmann F,
Ginestoux C,
Giudicelli V,
Duroux P.
Use of IMGT(®) databases and tools for antibody engineering and humanization. Methods Mol Biol 2012; 907: 3-37
42
Biasini M,
Bienert S,
Waterhouse A.
, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014; 42 (Web Server issue): W252-8
43
Pardon E,
Laeremans T,
Triest S.
, et al. A general protocol for the generation of nanobodies for structural biology. Nat Protoc 2014; 9 (03) 674-693
44
Saerens D,
Pellis M,
Loris R.
, et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol 2005; 352 (03) 597-607
45
Könning D,
Zielonka S,
Grzeschik J.
, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol 2017; 45: 10-16
47
Spiess C,
Zhai Q,
Carter PJ.
Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67 (2, Pt A): 95-106
51
Behdani M,
Zeinali S,
Karimipour M.
, et al. Development of VEGFR2-specific nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N Biotechnol 2013; 30 (02) 205-209
